旅行者中黄热病疫苗血清转化率。
Yellow fever vaccine seroconversion in travelers.
机构信息
Mount Auburn Hospital, Cambridge, Massachusetts, USA.
出版信息
Am J Trop Med Hyg. 2011 Oct;85(4):748-9. doi: 10.4269/ajtmh.2011.11-0363.
Abstract
To assess immunity after yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.
摘要
为了评估黄热病（YF）17D 活疫苗接种后的免疫情况，我们测量了 YF 初免旅行者在接种前、接种后 21 天和 8 个月的抗体水平。研究纳入 30 例受试者，100%的受试者在接种后 21 天提供血清，86.6%的受试者在接种后 8 个月提供血清。所有受试者在第 21 天均发生血清转化，抗 YF 抗体的几何平均滴度在第 21 天至第 8 个月从 6451 下降至 1246。本研究证实了活疫苗接种可实现高比例的血清转化率。
相似文献
1
Yellow fever vaccine seroconversion in travelers.旅行者中黄热病疫苗血清转化率。
Am J Trop Med Hyg. 2011 Oct;85(4):748-9. doi: 10.4269/ajtmh.2011.11-0363.
2
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.日本脑炎嵌合病毒减毒活疫苗与黄热病17D疫苗的同时或序贯接种：安全性和免疫原性的随机双盲II期评估
Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.
3
Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.伤寒和黄热病疫苗与四价脑膜炎球菌 ACWY 结合疫苗同时接种在健康成年人中的安全性和免疫原性。
J Travel Med. 2015 Jan-Feb;22(1):48-56. doi: 10.1111/jtm.12164. Epub 2014 Oct 13.
4
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.减毒活嵌合黄热2型登革热疫苗（ChimeriVax-DEN2）：安全性和免疫原性的I期临床试验：黄热预免疫对诱导针对所有4种登革热血清型的交叉中和抗体反应的影响。
Hum Vaccin. 2006 Mar-Apr;2(2):60-7. doi: 10.4161/hv.2.2.2555. Epub 2006 Mar 15.
5
Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.波士顿地区旅行者前往黄热病病毒传播风险国家的偏好和决策需求：对医疗保健提供者的启示。
J Travel Med. 2014 Jul-Aug;21(4):266-71. doi: 10.1111/jtm.12119. Epub 2014 Apr 16.
6
Yellow fever vaccine: an effective vaccine for travelers.黄热病疫苗：一种对旅行者有效的疫苗。
Hum Vaccin Immunother. 2014;10(1):126-8. doi: 10.4161/hv.26549. Epub 2013 Sep 20.
7
Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.黄热病疫苗接种后 3-4 年抗黄热病病毒免疫球蛋白 m 抗体的检测。
Am J Trop Med Hyg. 2012 Dec;87(6):1112-5. doi: 10.4269/ajtmh.2012.12-0182. Epub 2012 Oct 29.
8
Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.黄热病疫苗在人类免疫缺陷病毒感染者中的免疫原性和保护持续时间：系统评价。
Clin Microbiol Infect. 2021 Jul;27(7):958-967. doi: 10.1016/j.cmi.2021.03.004. Epub 2021 Apr 1.
9
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.嵌合黄病毒疫苗（ChimeriVax）的临床原理验证：针对黄病毒感染的重组减毒活疫苗。
Vaccine. 2002 Jan 15;20(7-8):1004-18. doi: 10.1016/s0264-410x(01)00457-1.
10
Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.2009-2011 年期间，美国环球旅行者接触网（US Global TravEpiNet）旅行者前往有黄热病病毒传播风险的国家旅行的特点和黄热病疫苗使用情况。
Am J Trop Med Hyg. 2013 May;88(5):954-961. doi: 10.4269/ajtmh.12-0463. Epub 2013 Mar 4.
引用本文的文献
1
A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine.一种经质量验证的黄热病疫苗免疫反应的数学计算模型。
BMC Immunol. 2018 May 25;19(1):15. doi: 10.1186/s12865-018-0252-1.
2
Mathematical modeling based on ordinary differential equations: A promising approach to vaccinology.基于常微分方程的数学建模：疫苗学的一种有前景的方法。
Hum Vaccin Immunother. 2017 Feb;13(2):484-489. doi: 10.1080/21645515.2017.1264774. Epub 2016 Dec 27.
3
The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.17D - 204疫苗株诱导的针对强毒性黄热病毒的保护作用是由体液免疫和CD4 + 而非CD8 + T细胞介导的。
PLoS Pathog. 2016 Jul 27;12(7):e1005786. doi: 10.1371/journal.ppat.1005786. eCollection 2016 Jul.
4
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.利用从黄热病疫苗成功中获得的知识指导登革热疫苗的研发。
Cell Mol Immunol. 2016 Jan;13(1):36-46. doi: 10.1038/cmi.2015.76. Epub 2015 Oct 5.
5
Optimization of the cutoff value for a commercial anti-dengue virus IgG immunoassay.商用抗登革病毒IgG免疫测定临界值的优化
Clin Vaccine Immunol. 2013 Mar;20(3):358-62. doi: 10.1128/CVI.00429-12. Epub 2013 Jan 9.
6
Experimental therapies for yellow fever.黄热病的实验疗法。
Antiviral Res. 2013 Feb;97(2):169-79. doi: 10.1016/j.antiviral.2012.12.002. Epub 2012 Dec 10.
本文引用的文献
1
Cases of travel-acquired dengue fever in Denmark 2001-2009.2001-2009 年丹麦的输入性登革热病例。
Clin Microbiol Infect. 2012 Feb;18(2):171-6. doi: 10.1111/j.1469-0691.2011.03543.x. Epub 2011 Jul 11.
2
An inactivated cell-culture vaccine against yellow fever.一种针对黄热病的灭活细胞培养疫苗。
N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.
3
Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.针对17D黄热病疫苗加强免疫的中和抗体反应。
Vaccine. 2006 Apr 5;24(15):2843-9. doi: 10.1016/j.vaccine.2005.12.055. Epub 2006 Jan 18.
4
Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus.B组节肢动物传播病毒的免疫学研究。I. 17D株黄热病疫苗对既往感染日本脑炎病毒的人类受试者诱导的中和抗体谱拓宽。
Am J Trop Med Hyg. 1962 Jul;11:550-61.
5
6
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.两种黄热病17D疫苗（ARILVAX和YF-VAX）在一项III期多中心双盲临床试验中的安全性和免疫原性比较
Am J Trop Med Hyg. 2002 May;66(5):533-41. doi: 10.4269/ajtmh.2002.66.533.
7
Prevention of yellow fever in persons traveling to the tropics.前往热带地区人员的黄热病预防。
Clin Infect Dis. 2002 May 15;34(10):1369-78. doi: 10.1086/340104. Epub 2002 Apr 25.
8
Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.两种17D黄热病疫苗的免疫原性和安全性比较。
Am J Trop Med Hyg. 1999 Jun;60(6):1045-50. doi: 10.4269/ajtmh.1999.60.1045.
9
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.17D 黄热病疫苗免疫后 30 - 35 年中和抗体的持续性。
Bull World Health Organ. 1981;59(6):895-900.
10
Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans.人类接种黄热病17D疫苗后主要免疫球蛋白类别的中和抗体反应。
Am J Epidemiol. 1971 Feb;93(2):122-9. doi: 10.1093/oxfordjournals.aje.a121232.
Zotero 插件